Valneva (VALN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $18
Moomoo NewsJan 23 06:34 ET · Ratings
Positive Outlook for Valneva: Favorable Vaccine Trials and Expanding Market Potential
TipRanksJan 23 06:27 ET
Kepler Capital Sticks to Their Buy Rating for Valneva (0OB3)
TipRanksJan 22 20:36 ET · Ratings
Valneva Reports Positive Phase 2 Results in Children for Its Chikungunya Vaccine and Announces Phase 3 Dose Decision
GlobeNewswireJan 22 11:45 ET
Express News | Valneva Shares Are Trading Higher After the Company Announced Its Vaccine Showed a Sustained Immune Response in Adolescents a Year After a Single Shot
BenzingaJan 21 15:09 ET
The biotechnology company Valneva (VALN.US) announced new data on the chikungunya virus vaccine, which is expected to be suitable for adolescents.
Chikungunya is a viral disease transmitted by mosquitoes, which the World Health Organization has classified as a major public health issue.
Zhitong FinanceJan 21 08:15 ET

Comments

Trytosaveabit

Jan 21 03:18

update

$Valneva (VALN.US)$ Reported Monday, Valneva Reports 98.3% Seroresponse One Year After Single Chikungunya Vaccine In Adolescents
Benzinga· 23 mins ago
The one-year VLA1553-321 data showed that a single-dose vaccination induced a high, sustained immune response in an immunogenicity subset of participants who were CHIKV negative at baseline, with a seroresponse rate of 98.3% (232 out of 236 participants) one year after vaccination (Day 360) compared to 99.1% (232 out of 234 participants) afte...

Trytosaveabit

Nov 26, 2024 11:05

Watching

$Valneva (VALN.US)$ Valneva Submits Label Extension Application For Its Chikungunya Vaccine, IXCHIQ, To The U.S. FDA To Potentially Include Adolescents And Antibody Persistence Up To 2-Years

2

Chad Dunbar

Oct 31, 2024 14:42

Vaccine that nobody is talking about has potential…

$Valneva (VALN.US)$
I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine sched...

6

Trytosaveabit

Sep 3, 2024 08:15

Update

$Valneva (VALN.US)$ Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate
Drug makers Pfizer Inc. (PFE) and Valneva SE (VALN) announced Tuesday positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
Pfizer aims to submit a Biologics License Application or BLA to the U.S. Food and Drug Ad...

2

Trytosaveabit

Jul 22, 2024 05:30

News

$Valneva (VALN.US)$ Valneva is set to receive up to $41.3 million from CEPI and the EU to enhance access to IXCHIQ®, the world’s first chikungunya vaccine, particularly in low- and middle-income countries. The funding will bolster clinical trials in vulnerable groups and support technology transfer to additional manufacturers, ensuring wider distribution in regions at risk of chikungunya outbreaks. With approvals already in place in the U.S., Canada, and Europe, the company aims to extend the...

1

2

VALN Valneva

Trade Overview

Capital Trend

News

Comments

Trending Stocks